Pure Global

Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study - Trial NCT04880746

Access comprehensive clinical trial information for NCT04880746 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ruijin Hospital and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 266 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04880746
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT04880746
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
Efficacy and Safety of Cladribine Combined With BEAC ( Semustine, Etoposide, Cytarabine, Cyclophosphamide) Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

Study Focus

BEAC

Interventional

drug

Sponsor & Location

Ruijin Hospital

Shanghai, China

Timeline & Enrollment

Phase 3

Oct 17, 2020

Oct 17, 2025

266 participants

Primary Outcome

Progression free survival

Summary

This multi-center clinical study will evaluate the efficacy and safety of Cladribine Combined
 With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma.

ICD-10 Classifications

Peripheral T-cell lymphoma, not elsewhere classified
Cutaneous T-cell lymphoma, unspecified
Mature T/NK-cell lymphomas
Angioimmunoblastic T-cell lymphoma
Other mature T/NK-cell lymphomas

Data Source

ClinicalTrials.gov

NCT04880746

Non-Device Trial